Drug
Carfilzomib clinical trials
Also written Kyprolis and PR-171.
- studies test it
- 165
- open now
- 20
- in phase 3
- 16
- first study started
- 2007
Keep track of what changes. Save the carfilzomib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
165 studies that test it; most in 2013 (22)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 10 |
| 2012 | 9 |
| 2013 | 22 |
| 2014 | 19 |
| 2015 | 14 |
| 2016 | 5 |
| 2017 | 11 |
| 2018 | 9 |
| 2019 | 15 |
| 2020 | 7 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 74
- Phase 2
- 106
- Phase 3
- 16
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 38 · Other 127
Amgen (21) · M.D. Anderson Cancer Center (9) · National Cancer Institute (NCI) (8) · University of Chicago (7) · Hackensack Meridian Health (5) · Memorial Sloan Kettering Cancer Center (5) · Mayo Clinic (5) · Emory University (4)
Often tested with
Tested in the same studies.
Dexamethasone (86) · Lenalidomide (34) · Daratumumab (20) · Pomalidomide (17) · Cyclophosphamide (12) · Isatuximab (8) · Bortezomib (8) · Melphalan (8)
Studies
Open first, then newest update. How each study uses carfilzomib is read from its arms, and is right about nine times in ten.
Testing it · 165
- Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyNot yet recruitingPhase 1National Cancer Institute (NCI)NCT07715903Written as Carfilzomib
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBelRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06918990Written as Carfilzomib
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingPhase 1K36 Therapeutics, Inc.NCT05651932Written as Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07222761Written as Carfilzomib
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Carfilzomib
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingPhase 2University of ChicagoNCT05789303Written as Carfilzomib
- Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple MyelomaRecruitingPhase 1Hackensack Meridian HealthNCT03909412Written as Carfilzomib
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingPhase 2Hackensack Meridian HealthNCT04661137Written as Carfilzomib
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2Natalie CallanderNCT07479979Written as Carfilzomib
- Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseaseRecruitingPhase 2Roswell Park Cancer InstituteNCT06627751Written as Carfilzomib
- SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Roswell Park Cancer InstituteNCT06622005Written as Carfilzomib
- KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS SyndromeRecruitingPhase 2Shanghai Changzheng HospitalNCT07652879Written as CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
- Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 1City of Hope Medical CenterNCT06249282Written as Carfilzomib
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Benjamin T Diamond, MDNCT05896228Written as Carfilzomib
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 2SanofiNCT06356571Written as Carfilzomib
- Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary DiseaseRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06793475Written as Carfilzomib
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingPhase 4The First Affiliated Hospital of Soochow UniversityNCT06409702Written as Carfilzomib
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingPhase 2Wuhan Union Hospital, ChinaNCT06140966Written as Carfilzomib
- Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMMNot yet recruitingPhase 2Dong-A University HospitalNCT05909826Written as Carfilzomib
- A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)Enrolling by invitationPhase 2Landspitali University HospitalNCT03815279Written as Carfilzomib
See all 165 studies that test carfilzomib →
Given in every arm · 50 — carfilzomib is usual care beside what is tested
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationPhase 2SanofiNCT05669989Written as Carfilzomib
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as Carfilzomib
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingPhase 1/2BeOne MedicinesNCT04973605Written as Carfilzomib
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06615479Written as Carfilzomib
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)RecruitingPhase 2GlaxoSmithKlineNCT07227311Written as Carfilzomib
- A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingPhase 4The First Affiliated Hospital of Soochow UniversityNCT07709884Written as Carfilzomib
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Carfilzomib
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Carfilzomib
- Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple MyelomaActive, not recruitingPhase 2University of Colorado, DenverNCT04925193Written as Carfilzomib
- A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple MyelomaTerminatedPhase 1/2Hoffmann-La RocheNCT06055075Written as Carfilzomib
- A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT05050097Written as Carfilzomib
- A Study of DaratumumabActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05438043Written as Carfilzomib
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Active, not recruitingPhase 3Bristol-Myers SquibbNCT05552976Written as Carfilzomib
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomideActive, not recruitingPhase 1/2University of Alabama at BirminghamNCT05434689Written as Carfilzomib
- Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple MyelomaWithdrawnPhase 1Roswell Park Cancer InstituteNCT07082270Written as Carfilzomib
- Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomideActive, not recruitingPhase 1/2PETHEMA FoundationNCT05060627Written as Carfilzomib
- Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.CompletedPhase 2Mario BoccadoroNCT02203643Written as Carfilzomib
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple MyelomaActive, not recruitingPhase 1/2CelgeneNCT02773030Written as Carfilzomib
- Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma PatientsCompletedPhase 3SanofiNCT03275285Written as carfilzomib
- A Study of Modakafusp Alfa in Adult Participants With Multiple MyelomaTerminatedPhase 1Teva Branded Pharmaceutical Products R&D LLCNCT05556616Written as Carfilzomib
Showing 20 of 50.
As the comparator · 8 — what is tested is compared with carfilzomib
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingPhase 2National Cancer Institute (NCI)NCT06948084Written as Carfilzomib
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentRecruitingPhase 1/2National Cancer Institute (NCI)NCT07463807Written as Carfilzomib
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingPhase 3Hoffmann-La RocheNCT07555938Written as Carfilzomib
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingPhase 3AstraZenecaNCT07391657Written as Carfilzomib
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingPhase 3PfizerNCT06152575Written as Carfilzomib
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3AbbVieNCT07728188Written as Carfilzomib
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT06413498Written as Carfilzomib
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnPhase 3CelgeneNCT06232707Written as Carfilzomib
Codes
What other systems call carfilzomib · ClinicalTrials.gg INT005194
- MeSH (NLM) C524865carfilzomibOne source NLM
- UNII (FDA) 72X6E3J5ARCARFILZOMIBConfirmed FDA, NLM, Wikidata
- RxNorm 1302966Confirmed FDA, Wikidata
- Wikidata Q15366934carfilzomibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C52196CarfilzomibOne source FDA
- DrugBank DB08889One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C524865 | carfilzomib | One source NLM |
| UNII (FDA) | 72X6E3J5AR | CARFILZOMIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1302966 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15366934 | carfilzomib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C52196 | Carfilzomib | One source FDA |
| DrugBank | DB08889 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.